A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
about
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID micePreparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza.Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus.Immunoglobulin: production, mechanisms of action and formulations.Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.Prions and protein-folding diseases.Immunoglobulin replacement therapy for primary immunodeficiencies.Intravenous immunoglobulin in the treatment of neurologic disorders.Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.A prion reduction filter does not completely remove endogenous prion infectivity from sheep blood.Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process.Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG.
P2860
Q30361437-3CB2FC71-0435-4F0A-9CEE-B545D32D2EB5Q30407946-4F87943D-330F-4F1E-A619-FE597245483EQ34529911-001CFC7C-CB5A-48EC-AACF-95FA21D8EE09Q36153609-4DEDEF3E-E83C-41D5-AD15-952C65188C71Q37737558-D1DBDFD6-C8AA-411C-9D7B-173FCCB2A024Q37863713-1E8758E6-AC9E-44D1-9C4B-978863D23DA4Q38257643-6F12D57E-63DB-4619-A948-C99A268F0FD5Q38495457-022E9477-D138-42C3-A9E8-39EC4001D72CQ38569717-2347C40A-44B6-4285-BFF3-B885E0F1700CQ38820352-7BAD14CA-13A8-48C2-AD4F-DE48D6F82FAFQ41191548-C5AF8DAF-BC37-4399-9D0A-4B78C72F25D9Q41329340-53A8D3D1-AB2D-4E39-87E4-32F3D020A3E1Q42004859-2EB118F3-D00C-4996-9A3F-1B78BC03CD4CQ50967516-569E0E72-332F-4827-BA87-C36DA2E3BD08
P2860
A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A new liquid intravenous immun ...... and prion reduction capacity.
@en
A new liquid intravenous immun ...... and prion reduction capacity.
@nl
type
label
A new liquid intravenous immun ...... and prion reduction capacity.
@en
A new liquid intravenous immun ...... and prion reduction capacity.
@nl
prefLabel
A new liquid intravenous immun ...... and prion reduction capacity.
@en
A new liquid intravenous immun ...... and prion reduction capacity.
@nl
P2093
P2860
P1433
P1476
A new liquid intravenous immun ...... and prion reduction capacity.
@en
P2093
G Poelsler
H P Schwarz
J Kindermann
T Hämmerle
W Teschner
P2860
P304
P356
10.1111/J.1423-0410.2007.01016.X
P577
2007-12-19T00:00:00Z